---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040009"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:41:39.837339+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix Q3 2023 net loss $3.8M; cash $21.3M, runway into Q1 2025

## Summary
- Revenue $1.8M (-$0.1M YoY); net loss $3.8M ($1.03/share) vs $5.1M loss in prior year.
- Cash $21.3M, down from $35.6M at Dec 2022; projected runway into Q1 2025.
- PUR1900 Phase 2b in ABPA ongoing; topline data expected H2 2024.
- PUR3100 IND cleared for Phase 2 in acute migraine; study start contingent on financing.
- PUR1800 Phase 1b completed; seeking partnership for Phase 2.

## SEC filing metadata
- accession: 0001493152-23-040009
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315223040009/0001493152-23-040009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315223040009/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040009
- JSON: https://secwatch.observer/filing/0001493152-23-040009.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040009.txt

## Key facts
- Earnings Releases
  Pulmatrix, Inc. reported the third fiscal quarter ended September 30, 2023 results: revenue $1.8 million.
  - Period: the third fiscal quarter ended September 30, 2023
  - Revenue: $1.8 million
  - Result: reported results
  source text: plans to pursue partnership opportunities to advance PUR1800 into a potential Phase 2 clinical trial. Third Quarter 2023 Financial Results Revenues decreased $0.1 million to $1.8 million for the three months ended September 30, 2023 compared to $1.9 million for the three months ended September 30, 2022. The decrease is related to the Company’s revenues recognized
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574235/000149315223040009/0001493152-23-040009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.